SCHEMBL20129033

SCHEMBL20129033

CC(C)(C)OC(=O)N1CC(OCCCOCCCO[C@H]2C[C@H](C)C2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.45
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HPGD P15428 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RECQL P46063 1/20 0.34
EPHX1 P07099 1/20 0.34
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129039 0.90 NR1H2 (0.45) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL27098085 0.89 NR1H2 (0.38) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL27097799 0.86 NR1H2 (0.43) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL20129034 0.86 NR1H2 (0.43) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL20129252 0.86 NR1H2 (0.43) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL20129035 0.86 NR1H2 (0.47) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL20129254 0.86 NR1H2 (0.47) NR1H2PRMT5WDR77MEN1ALDH1A1
SCHEMBL20129273 0.86 HPGD (0.41) PRMT5WDR77HPGDUSP2SMN1; SMN2
SCHEMBL20129283 0.86 HPGD (0.41) PRMT5WDR77HPGDUSP2SMN1; SMN2
SCHEMBL27097889 0.85 NR1H2 (0.49) NR1H2PRMT5WDR77MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NR1H2 3409/4885PRMT5 584/4885WDR77 1631/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 NR1H2 3751/4885PRMT5 547/4885WDR77 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.